*

Hitt og þetta 17. ágúst 2007

aap posts first-half sales of EUR 12.7 million (+38%) and EBIT of EUR 0.8 million (-51%)

aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment, achieved after consolidation with the Dutch Fame Medical Group a 38% growth in sales in the first six months of the financial year to EUR 12.7 million (previous year: EUR 9.2 million), and an operating result of EUR 0.8 million (previous year: EUR 1.7 million). This trend in results is due to a weak first quarter. However, the Q2 result already marks a return to the previous year's high level. +-------------------------------------------------------------------+ | In EUR million | Q2/2007 | Q2/2006 | Change on | | | including Fame | | Year | | | | | | |---------------------+----------------+------------+---------------| | Sales | 12.7 | 9.2 | +38% | |---------------------+----------------+------------+---------------| | EBITDA | 1.9 | 2.4 | -23% | |---------------------+----------------+------------+---------------| | EBIT | 0.8 | 1.7 | -51% | |---------------------+----------------+------------+---------------| | EBT | 0.7 | 1.7 | -61% | |---------------------+----------------+------------+---------------| | Net period result | 0.4 | 1.0 | -64% | |---------------------+----------------+------------+---------------| | Equity (Ratio) | 22.1 (38%) | 21.6 (77%) | +3% | |---------------------+----------------+------------+---------------| | Balance sheet total | 59.0 | 28.0 | +111% | |---------------------+----------------+------------+---------------| | Employees | 270 | 161 | +68% | +-------------------------------------------------------------------+ In the first half of 2007 the Group earned an EBITDA of EUR 0.8 million (previous year: EUR 1.7 million). Group EBIT was EUR 0.8 million (previous year: EUR 1.7 million), and EBT EUR 0.7 million (previous year: EUR 1.7 million). With total assets of EUR 59.0 million (previous year: EUR 28.0 million) the equity ratio is currently 38% because the capital increase has not yet been implemented. After the capital increase it would be 72%. In the second quarter aap succeeded in laying the groundwork for a successful financial year. aap showed a double-digit increase in international sales in the Trauma & Joint Reconstruction segment, while in the Biomaterials segment the company signed exclusive worldwide (excluding the U.S.) sales agreements with Zimmer (new Hi-Fatigue® bone cement) and Medtronic (Nanostim® nano-based bone replacement material). These two companies are world market leaders in their fields (orthopedics and spine), and aap expects the two new partnerships to generate substantial product sales in the future. aap is currently in the process of taking over another product in the spine segment with a view to further expanding its biological implants business. For the full year 2007 aap anticipates sales of EUR 28 million to EUR 30 million (previous year: EUR 18.5 million) and an EBIT margin in excess of 10%. However, since business depends on product approvals and large international customers, this may be subject to fluctuations. The full report on aap Implantate AG's second quarter of 2007 is available to download at www.aap.de. _ aap is a medical technology company that develops, manufactures and markets biomaterials and implants for trauma and joint reconstruction. Its product portfolio includes bone cements, bone graft substitutes, antibiotical carriers, implants for fracture healing and joint replacement. In addition to its Berlin headquarters the company has locations in Dieburg and Obernburg near Frankfurt am Main as well as at Nijmegen in the Netherlands. aap Implantate AG has been listed in the Prime Standard segment at the Frankfurt stock exchange since May 16, 2003. Please address any queries to: aap Implantate AG, Nanette Hüdepohl, Investor & Public Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9133; fax: +49 30 7501 9290; n.huedepohl@aap.de --- End of Message --- aap Implantate AG Lorenzweg 5 Berlin Germany WKN: 506660; ISIN: DE0005066609; Index: CDAX, Prime All Share, TECH All Share; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;